title: Hypoxic tolerance induction in rat brain slices following 3-nitropropionic acid pretreatment as revealed by dynamic changes in glucose metabolism.
abstract: Pretreatment with 3-nitropropionic acid (3-NPA) has been shown to induce tolerance to ischemic/hypoxic brain damage. However, regional differences in tolerance induction by 3-NPA and the degree to which impaired glucose metabolism due to 3-NPA pretreatment itself is directly involved remain unknown. To evaluate these issues using dynamic positron autoradiography with [(18)F]2-fluoro-2-deoxy-D-glucose, the cerebral glucose metabolic rate (CMRglc) was serially measured before and after hypoxia-loading in rat brain slices pretreated with 3-NPA. CMRglc before hypoxia did not significantly differ between the 3-NPA pretreatment group and control group. The 3-NPA-associated recovery of CMRglc after reoxygenation was observed in the frontal cortex, hippocampus, and cerebellum, but not in the striatum and thalamus. Thus, we demonstrated the induction of region-specific hypoxic tolerance after 3-NPA pretreatment using CMRglc maintenance as an index of neuronal viability, and it is unlikely that this induction is associated with the persistence of impaired glucose metabolism due to 3-NPA pretreatment.
authors.affiliation: Department of Neuropsychiatry, Fukui Medical University, Fukui, Japan.
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Maruoka
authors.forename: Tetsuhito
authors.initials: T
authors.lastname: Murata
authors.forename: Naoto
authors.initials: N
authors.lastname: Omata
authors.forename: Yasuhisa
authors.initials: Y
authors.lastname: Fujibayashi
authors.forename: Yoshiharu
authors.initials: Y
authors.lastname: Yonekura
authors.forename: Yuji
authors.initials: Y
authors.lastname: Wada
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001921:Brain / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000378:metabolism; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D004734:Energy Metabolism / Q000187:drug effects* / Q000502:physiology; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics; D005947:Glucose / Q000378:metabolism*; D020925:Hypoxia-Ischemia, Brain / Q000000981:diagnostic imaging / Q000378:metabolism / Q000517:prevention & control*; D019194:Ischemic Preconditioning / Q000379:methods*; D008297:Male; D009474:Neurons / Q000000981:diagnostic imaging / Q000187:drug effects / Q000378:metabolism; D009574:Nitro Compounds; D011422:Propionates / Q000494:pharmacology*; D011877:Radionuclide Imaging; D051381:Rats; D017208:Rats, Wistar; D020127:Recovery of Function / Q000187:drug effects / Q000502:physiology; D015427:Reperfusion Injury / Q000000981:diagnostic imaging / Q000378:metabolism / Q000517:prevention & control
chemical_list: D000959:Antihypertensive Agents; D009574:Nitro Compounds; D011422:Propionates; D019788:Fluorodeoxyglucose F18; D005947:Glucose; C015392:3-nitropropionic acid